A retrospective study of head and neck re-irradiation for patients with recurrent or second primary head and neck cancer: the McGill University experience

Journal of Otolaryngology-Head & Neck Surgery

George Shenouda³  Khalil Sultanem²  Crystal Holly¹  Siavosh Vakilian³  Rolina Al-Wassia⁴ 

[1] Department of Clinical Epidemiology, McGill University, Montreal, Québec, Canada;Radiation Oncology, Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Québec, Canada;Department of Radiation Oncology, McGill University Health Centre, McGill University, Montreal, Québec, Canada;Department of Radiation Oncology, King Abdulaziz University, Abdullah Suleiman Street, Jeddah, 21589, Saudi Arabia

关键词: Squamous cell carcinoma;    Head and neck;    Re-irradiation;   

Others  :  1223812
DOI  :  10.1186/s40463-015-0084-4

 received in 2015-01-07, accepted in 2015-08-23,  发布年份 2015

【 摘 要 】

Background

We report our experience with patients who received re-irradiation to the head and neck area for locoregional recurrences (LRR) or second primaries (SP) in a previously irradiated field.

Methods

We reviewed 27 consecutive patients with a diagnosis of LRR or SP head and neck carcinoma treated with a second course of radiotherapy between April 2004 and July 2012. The main outcome measures were local control, overall survival, and complications. The results are expressed as actuarial values using the Kaplan–Meier estimates.

Results

The median follow-up time was 24.7 months (range: 11 days–79.3 months). There were 23 males and four females with a median age of 61 years (range: 40–87 years). The actuarial overall survival rates at 1, 2, and 5 years were 77, 59, and 57 %, respectively. The actuarial local control rate was 80, 52, and 52 % at 1, 2, and 5 years, respectively. Three patients developed systemic metastases. The rate of grade 3 toxicity was 26 %, and that of grade 4 toxicity was 3 %. There were two treatment-related deaths (grade 5 toxicity).

Conclusions

Continuous course re-irradiation in patients with LRR or SP head and neck cancer is feasible with acceptable toxicity. With current encouraging rates of local control and overall survival, this option should be discussed with patients who have few alternative therapeutic options.

【 授权许可】

   
2015 Al-Wassia et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Bachar GY, Goh C, Goldstein DP, O'Sullivan B, Irish JC. Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur Arch Otorhinolaryngol. 2010; 267:295-301.
• [2]Caponigro F, Massa E, Manzione L, Rosati G, Biglietto M, De Lucia L, Squotti C, Sganga P, Avallone A, Comella P, Mantovani G, Cormella G. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol. 2001; 12:199-202.
• [3]Kasperts N, Slotman B, Leemans CR, Langendijk JA. A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol. 2005; 41:225-243.
• [4]McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys. 2012; 82:1083-1089.
• [5]Biagioli MC, Harvey M, Roman E, Raez LE, Wolfson AH, Mutyala S, Han HS, Markoe A. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 69:1067-1073.
• [6]Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, Hamoir M, Géry B, Julieron M, Castaing M, Bardet E, Grégoire V, Bourhis J. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008; 26:5518-5523.
• [7]Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, Witt ME, Haraf DJ. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006; 64:382-391.
• [8]Goldstein DP, Karnell LH, Yao M, Chamberlin GP, Nguyen TX, Funk GF. Outcomes following reirradiation of patients with head and neck cancer. Head Neck. 2008; 30:765-770.
• [9]Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol. 2006; 78:306-312.
• [10]Kharofa J, Choong N, Wang D, Firat S, Schultz C, Sadasiwan C, Wong S. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. Int J Radiat Oncol Biol Phys. 2012; 83:690-695.
• [11]Berger B, Belka C, Weinmann M, Bamberg M, Budach W, Hehr T. Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol. Strahlenther Onkol. 2010; 186:255-261.
• [12]Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27:843-850.
• [13]Balermpas P, Keller C, Hambek M, Wagenblast J, Seitz O, Rödel C, Weiss C. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys. 2012; 83:e377-e383.
• [14]Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009; 73:399-409.
• [15]Sher DJ, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010; 116:4761-4768.
• [16]Lee N, Chan K, Bekelman JE, Zhung J, Mechalakos J, Narayana A, Wolden S, Venkatraman ES, Pfister D, Kraus D, Shah J, Zelefsky MJ. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 68:731-740.
• [17]Benchalal M, Bachaud JM, François P, Alzieu C, Giraud P, David JM, Daly-Schveitzer N. Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study. Radiother Oncol. 1995; 36:203-210.
• [18]Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011; 80:669-676.
• [19]Comet B, Kramar A, Faivre-Pierret M, Dewas S, Coche-Dequeant B, Degardin M, Lefebvre JL, Lacorniere T, Lartigau EF. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012; 84:203-209.
• [20]Hoebers F, Heemsbergen W, Moor S, Lopez M, Klop M, Tesselaar M, Rasch C. Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys. 2011; 81:e111-e118.
• [21]Popovtzer A, Gluck I, Chepeha DB, Teknos TN, Moyer JS, Prince ME, Bradford CR, Eisbruch A. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys. 2009; 74:1342-1347.
• [22]Creak AL, Harrington K, Nutting C. Treatment of recurrent head and neck cancer: re-irradiation or chemotherapy? Clin Oncol (R Coll Radiol). 2005; 17:138-147.
• [23]Mendenhall WM, Mendenhall CM, Malyapa RS, Palta JR, Mendenhall NP. Re-irradiation of head and neck carcinoma. Am J Clin Oncol. 2008; 31:393-398.
• [24]Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol. 2006; 24:2653-2658.
• [25]Scala LM, Hu K, Urken ML, Jacobson AS, Persky MS, Tran TN, Smith ML, Schantz S, Harrison LB. Intraoperative high-dose-rate radiotherapy in the management of locoregionally recurrent head and neck cancer. Head Neck. 2013; 35(4):485-92.